drugset / Trial / NCT06721286

Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma

NCT06721286 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

This study was a randomized controlled trial to evaluate the efficacy and safety of toripalimab combined with GemCis (gemcitabine and cisplatin) as preoperative neoadjuvant therapy for resectable ICC at high risk of recurrence.

Timeline

Start
2024-11-12
Primary completion
2026-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 25 mg/m2 —
Subject Gemcitabine Small molecule 1000 mg/m2 —
Subject Teripalimab Monoclonal antibody 240 mg Intravenous